U.S. market Closed. Opens in 1 day 9 hours 19 minutes

GALT | Galectin Therapeutics Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for GALT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (16%)

Company Industry
P/E Ratio (TTM) -3.50 -22.08
PEG Ratio (TTM) 0.47 15.66
P/S Ratio (TTM) 1,938.41 49.38
P/B Ratio (TTM) -1.89 18.85
P/FCF Ratio (TTM) -4.73 -3.07
Price to 5YR AVG Earnings Ratio -4.78 -3.42
Price to 5YR AVG FCF Ratio -6.47 -9.04

Profitability (50%)

Company Industry
ROA (TTM) -160.13% -5.15%
ROE (TTM) 67.01% 16.37%
Net Profit Margin (TTM) -55,356.25% -2,030.32%
ROIC 5YR AVG 401.04% 15.65%

Growth (0%)

4QTR AVG 3YR AVG 5YR AVG
EPS -7.87% -20.42% -19.58%
Revenue -25.00% N/A N/A
Net Income -8.22% -34.58% -27.01%
Cash Flow -16.38% -38.16% -29.68%

Health (18%)

Company Industry
Current Ratio (TTM) 1.87 6.19
Quick Ratio (TTM) 1.87 5.91
D/E Ratio (TTM) -1.14 -15.10
Interest Coverage (TTM) -9.91 -1.60
Piotroski F-Score 3 5
Altman Z-Score N/A 14.02
LTL to 5YR AVG FCF -2.99 0.18
Shares Outstanding Growth 5YR AVG 7.73% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙